| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bbe675b46d686407d64e31a937562663
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7a39744c21a453d217de1f61d7c1b79a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-197
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-197
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate |
2021-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f27c68fa03c00077e0b65ab865dc9d40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75c6e52732a9c90daf13d637aaed96ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96cd61b09c479b14269ddc436976f8ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51d93b5433c43901ceb164eabda1187c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_864c66fa1b037efa9dbc9f9a13c41f8a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b285e804ea727295cdc26ae32e24bfee |
| publicationDate |
2022-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-4106741-A1 |
| titleOfInvention |
Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme |
| abstract |
The invention relates to a pharmaceutical composition comprising one or more stimulators of soluble guanylate cyclase (sGC), or a combination of at least one stimulator of sGC and at least one activator of sGC, for use in a method of treatment of a disease and/or a disorder that is/are associated with a deficiency of cyclic 3',5'-guanosine monophosphate in the patient to be treated. The invention also relates to a therapeutic combination comprising a first unit dose comprising an sGC stimulator and a second unit dose comprising an sGC activator. The invention also relates to a therapeutic combination comprising a first unit dose comprising a first sGC stimulator and a second unit dose comprising a second sGC stimulator, for use in a method for the treatment of a disease and/or a disorder that is/are associated with a deficiency of cyclic 3',5'-guanosine monophosphate in the patient to be treated. Furthermore, the invention relates to a kit comprising a pharmaceutical composition comprising one or more stimulators of sGC; a pharmaceutical composition comprising one or more stimulators of sGC and one or more activators of sGC; a therapeutic combination comprising a first unit dose comprising a first sGC stimulator and a second unit dose comprising a second sGC stimulator; or to a therapeutic combination comprising a first unit dose comprising an sGC stimulator and a second unit dose comprising an sGC activator. |
| priorityDate |
2020-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |